Grants for County governments - Health

This funding opportunity supports U.S. institutions in providing research education and mentorship for recent graduates from diverse backgrounds to prepare them for neuroscience doctoral programs.

This funding opportunity provides financial support for multidisciplinary research teams to investigate tuberculosis and its interactions with the host, aiming to improve understanding and treatment of the disease.

This funding opportunity provides financial support for innovative research projects that explore the complex relationship between adolescent social media use and mental health, particularly focusing on underserved youth populations.

This funding opportunity provides financial support to nonprofit organizations, government entities, and educational institutions in Ohio to enhance and sustain trauma-informed care initiatives across six designated regions.

This funding opportunity supports community-based organizations in Washington, DC, to enhance health and wellness initiatives in early childhood education facilities and public/charter schools, focusing on educator well-being, physical education, and environmental education.

This funding opportunity provides financial support for short-term projects that enhance local governance, infrastructure, education, and public safety in U.S. territories and freely associated states.

The FY 2024 Rural Emergency Medical Services (EMS) Training Program, funded by SAMHSA, aims to support rural EMS agencies in training EMS personnel, particularly to address substance use and co-occurring mental health disorders. Grants of up to $200,000 annually, for a project period of two years, are available to rural EMS agencies operated by local or tribal governments or as non-profit entities. Applications for the FY 2024 cycle are due by March 20, 2024, and for FY 2025 by March 20, 2025. This NOFO allows agencies that applied in a previous fiscal year but did not receive funding to reapply in subsequent years. The program’s key activities include training EMS personnel on identifying and managing substance use and mental health disorders, using trauma-informed and recovery-based approaches, and maintaining relevant certifications. Required activities encompass training on overdose reversal using naloxone, motivational interviewing, working with peer support specialists, and reporting overdose incidents to public health departments. Additionally, grantees can acquire necessary medical and emergency equipment with SAMHSA's prior approval. Optional activities include recruiting and training volunteer EMS personnel, acquiring personal protective equipment (PPE), and training on opioid overdose treatment using medications like buprenorphine. Eligibility for this funding is limited to rural EMS agencies as defined by either nonmetropolitan statistical areas or state designations of rural areas. Each application must include a project narrative of no more than ten pages, budget details, and a certification that the project will serve rural populations. There is a 10% matching funds requirement, and applicants must be registered with eRA Commons, Grants.gov, and SAM.gov before submission. Applications exceeding page or budget limits will not be reviewed. Evaluation criteria include the project's relevance to community needs, feasibility, and organizational capability to deliver training. Additional consideration is given to applications serving underserved communities and advancing DEIA principles. Awardees are required to submit progress reports at six and twelve months, as well as a final project report.

This funding opportunity supports collaborations between academic institutions and industry to develop innovative technologies that improve disease diagnosis, treatment, and management, particularly for underserved populations.

This program provides matching funds to municipalities and nonprofit organizations in Massachusetts for projects that preserve and enhance the history and experiences of veterans.

This funding opportunity supports research into how certain diabetes medications may influence cancer risk, encouraging studies that explore the underlying biological mechanisms involved.

This funding opportunity is designed for healthcare institutions and organizations in the U.S. to improve the management and outcomes of migraine patients in emergency departments.

This funding opportunity provides financial support to organizations working to combat domestic violence, dating violence, sexual assault, and stalking in rural communities across the U.S.

This grant provides funding for innovative research using invasive brain recording and stimulation techniques in humans to improve understanding of the neural circuits involved in mental health disorders.

The purpose of the NINDS Research Program Award (RPA) is to provide longer-term support, and increased freedom and flexibility, to Program Directors (PDs)/Principal Investigators (PIs), to allow them to redirect their time away from the administrative burden of writing and managing multiple grant applications and towards engaging in the lab. This RPA affords investigators at most career stages the opportunity to advance their long-term research goals, rigorously explore exciting research opportunities, and mentor students and postdoctorates, which support and align with the mission of NINDS. RPAs will support the overall research programs of NINDS-funded investigators for up to 8 years, at a level commensurate with a PD/PIs recent NINDS support (Part 2, Section II). This funding stability will provide eligible investigators increased security, allowing them to undertake research projects that require a longer timeframe or to embark upon research that breaks new ground. Research activities outside of the NINDS mission, or traditionally supported by another NIH Institute or Center, will not be considered through this program. Benefits of the RPA include: A more stable funding environment, facilitating the pursuit of longer-term research goals; Flexible funding, enabling investigators to pursue research opportunities as they arise, not tied to specific aims; Reduced time spent writing grant applications and managing multiple grant awards, allowing investigators to spend more time conducting and overseeing research; More time for PDs/PIs to mentor and foster a diverse workforce in their laboratories. NINDS is committed to enhancing the diversity and inclusiveness of the neuroscience workforce. A diverse NIH-supported scientific workforce, including individuals from underrepresented groups, fosters scientific innovation, enhances global competitiveness, contributes to robust learning environments, and improves the quality of the research. See the Notice of NIH

This funding opportunity supports researchers conducting observational studies to improve understanding and treatment of musculoskeletal, rheumatic, and skin diseases, with a focus on patient outcomes and disease progression.

This funding opportunity is designed to establish a center that will coordinate and advance research on whole person health by integrating diverse biomedical knowledge and fostering collaboration among researchers.

This funding opportunity supports researchers with active NCI U01 awards who want to integrate innovative cancer research technologies to improve their studies and advance cancer prevention, detection, diagnosis, and treatment.

This funding opportunity supports research to uncover genetic factors related to mental disorders in diverse populations, particularly those of non-European ancestry, while promoting community engagement and career development for early-career researchers.

Allergic reactions to drugs and vaccines are a serious public health concern. For the purpose of this notice of funding opportunity (NOFO), allergic reactions include not only IgE-mediated reactions, but other immune-mediated and largely unpredictable drug and vaccine reactions. Based on data from 2013-2014, each year in the United States there are an estimated 200,000 emergency department visits for adverse events related to antibiotics. In children 5 or younger, antibiotics cause more than half (56%) of estimated emergency department visits for adverse drug events and 82% of these visits are due to allergic reactions. Allergic reactions to antibiotics include immediate life-threatening reactions such as anaphylaxis, severe cutaneous reactions including Toxic Epidermal Necrolysis and Drug Reaction with Eosinophilia and Systemic Symptoms, and less severe reactions that still limit further use of the drugs. A label of antibiotic allergy leads to the use of alternative, frequently more expensive antibiotics, often with lower efficacy, which may contribute to antibiotic resistance as well as increased mortality and morbidity in hospitalized patients. While allergic reactions to vaccines are less common, the inability to receive a vaccine due to an allergy is problematic to the individual, and the perceived risk of allergic reactions to vaccines contributes to vaccine hesitancy creating a public health issue. Objectives The objective of this NOFO is to solicit innovative projects to study the mechanisms and management of vaccine or antibiotic drug allergy (research on allergic responses to anti-viral, anti-fungal and anti-parasitic drugs will also be considered). The scope of research into antibiotic or vaccine allergic reactions includes, but is not limited to, the following: IgE-mediated and other mechanisms of immediate allergic antibiotic or vaccine reactions Non-IgE-mediated urticarial reactions to antibiotics or vaccines Delayed-type hypersensitivity reactions to antibiotics or vaccines Severe cutaneous adverse antibiotic or vaccine reactions Biomarkers to identify people at risk for reaction or to confirm reactions to specific antibiotics or vaccines Host factors that may predispose to allergic reactions including, but not limited to, host microbiome, genetics, or inflammatory conditions Mechanisms by which specific infections may increase the risk of an allergic reaction to an antibiotic or vaccine Immunomodulatory approaches to treating or preventing immunologic adverse antibiotic or vaccine reactions A secondary objective of this NOFO is to expand the number of investigators working in the field of vaccine and antibiotic drug allergy. Early-stage investigators are encouraged to apply. UG3/UH3 phase transition and Milestones This funding opportunity is designed as a two-stage cooperative agreement in which Project Scientists from NIAID will work with the investigative team. It will support projects that are organized into a two-year UG3 phase followed by a three-year UH3 phase. The UG3 phase may include pilot, observational, or hypothesis-generating high-risk projects. Preliminary data may be helpful but are not required. The use of electronic health records to identify potential participants for mechanistic studies is allowed. The use of human samples such as those related to clinically indicated and routinely used interventions or tests is encouraged. The UG3 must include milestones to determine the success of the project at the end of this phase. Milestones may be negotiated or re-negotiated after award as this program includes the flexibility to quickly revise milestones and/or aims within the scope of the original peer-reviewed application. Following the completion of the UG3 phase, NIAID staff will review the progress made and make the determination on whether the project will continue to the UH3 phase. NIAID support for the UH3 is contingent upon progress made during the UG3 phase, meeting the milestones, programmatic priorities, the original UG3/UH3 peer review recommendations, and the availability of funds. Some projects might not transition from the UG3 to the UH3 phase. Projects supported by the UH3 phase are required to be hypothesis driven, mechanistic, and extend the work initiated by the UG3 phase. Program Director/Principal Investigator (PD/PI) Meeting Attendance A kick-off meeting and annual meetings will be organized by NIAID to facilitate interactions among recipients to share approaches, data, and methods, with the aim of developing a cadre of dedicated researchers to conduct antibiotic and vaccine allergy and advance mechanistic research. These meetings will convene yearly in the Rockville, Maryland area and will be held in person, though a virtual component will be available to allow broader participation from laboratory members. The PD/PI from each award is expected to attend the kickoff meeting and annual meetings in person. Applications that propose the following topics will be considered non-responsive and will not be reviewed: Adverse drug reactions that are predictable and/or related to pharmacologic properties of the drug such as toxicity or overdose Investigation into drugs that are not antibiotics or vaccines (however research on anti-viral, anti-fungal and anti-parasitic drugs is allowed) Investigations into Guillain-Barré Syndrome or drug-induced autoimmune reactions Investigations of central nervous system and other neurologic adverse responses Investigations into the pathogens rather than host allergic responses to the antibiotics or vaccines Applications that do not propose mechanistic research in the UH3 phase Vaccines that are administered via a route that is not the same route of administration as approved by the FDA Vaccines that are used as an immunotherapeutic (e.g. allergen immunotherapy) HIV/AIDS research

This funding opportunity supports collaborative research teams of diverse experts to tackle ambitious challenges in dental, oral, and craniofacial science, focusing on innovative solutions like non-opioid pain therapies and health disparity-reducing technologies.